Public-private partnerships shrank to 301 deals in 2013, down one-fifth from the year prior. Cancer again predominated (84 deals), with neurology (35 deals) and infectious disease (34 deals) second and third in the rankings (Fig. 1). Harvard University was the most active deal maker (Table 1), but both Johns Hopkins University and KU Leuven broke into the top 5 in 2013. AstraZeneca was the most active pharmaceutical firm (14 deals), whereas GlaxoSmithKline fell from its zenith of 14 deals in 2012 to just 9 last year (Fig. 2).

Figure 1: Deals by business area, 2013.
figure 1

Percentages rounded. Source: SciBx: Science-Business eXchange

Table 1 Academic-private partnerships 2013
Figure 2: Most active pharmas, 2013.
figure 2

Takeda also had four deals. Source: SciBX: Science-Business eXchange